Skip to main content

Table 6 Results of the base case cost-effectiveness analysis (year 2010 values) from the German hospital perspective (standard errors in parentheses)

From: A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

Type of surgery

Costs (€)

Incremental costs (€)

VTE events per person

Incremental effect (events avoided)

ICER (€ per event avoided)

THR

     

Rivaroxaban

33.8 (3.3)

31.8 (3.4)

0.005 (0.002)

0.007 (0.005)

1,564

Enoxaparin

2.05 (0.7)

 

0.012 (0.005)

  

TKR

     

Rivaroxaban

38.8 (3.9)

20.6 (5.6)

0.014 (0.005)

0.020 (0.007)

1,014

Enoxaparin

18.1 (4.3)

 

0.035 (0.009)

  
  1. THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, ICER = incremental cost-effectiveness ratio.